| Jun 24 |
Crypto under pressure, Good Buy or Goodbye: Market Domination
|
| Jun 24 |
Altimmune reports positive results in weight-loss drug trial
|
| Jun 24 |
Altimmune: Lean Muscle Fat Data Sends Stock Soaring - Competitors Will Take Note
|
| Jun 24 |
Biggest stock movers today: Crypto stocks, AFRM, ALNY, and more
|
| Jun 24 |
Altimmune jumps 13% on phase 2 pemvidutide results for obesity
|
| Jun 23 |
Altimmune Presents Data from Phase 2 MOMENTUM Trial of Pemvidutide in Obesity during Oral Presentation at the American Diabetes Association’s 84th Scientific Sessions
|
| Jun 22 |
Altimmune Presents Data on the Effect of Pemvidutide on Cardioinflammatory Lipids during Oral Presentation at American Diabetes Association’s 84th Annual Scientific Sessions
|
| Jun 21 |
Altimmune (NASDAQ:ALT) Is In A Good Position To Deliver On Growth Plans
|
| Jun 20 |
Altimmune to Participate in the Piper Sandler 2nd Annual Virtual Obesity Investor Day to Discuss ADA Takeaways
|
| Jun 18 |
Altimmune Announces Oral Presentations of Pemvidutide Clinical Data at Upcoming American Diabetes Association’s Scientific Sessions
|
